Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 13Nasopharyngeal Carcinoma 13Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 4Pancreatic Neoplasms 4Nasopharyngeal Neoplasms 4Melanoma 4Head and Neck Neoplasms 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Mesothelioma 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bile Duct Neoplasms 2Anus Neoplasms 2Adenocarcinoma Of Esophagus 2

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disorders of Sex Development × spartalizumab × Head & Neck × Clear all
NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Novartis

Phase 2 Completed
122 enrolled 28 charts
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡